<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01977235</url>
  </required_header>
  <id_info>
    <org_study_id>TDICC</org_study_id>
    <nct_id>NCT01977235</nct_id>
  </id_info>
  <brief_title>Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer</brief_title>
  <acronym>TDICC</acronym>
  <official_title>An Open, Randomized, Parallel Control, Multiple-center Phase II Trial of Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the gene polymorphism of uridine diphosphate glucuronosyl transferase 1A1(UGT1A1)is
      related to the side effect of diarrhea induced by irinotecan. UGT1A1 gene *28 (6/6 and 6/7)
      and *6 (G/G and G/A) is related to low probability of diarrhea and UGT1A1 gene *28 (7/7) and
      *6 (A/A)is related to high probability of diarrhea. The purpose of this study is to find out
      the efficacy and side effect between two different dosages of irinotecan combined with
      cisplatin scheme in extensive disease-small cell lung cancer with UGT1A1 gene *28 (6/6 and
      6/7)and *6 (G/G and G/A), based on the hypothesis that the UGT1A1 gene *28 (7/7) and *6
      (A/A)is few in the Chinese population and increasing the dose of irinotecan can improve the
      efficacy without increasing the side effect in the patients with UGT1A1 gene *28 (6/6 and
      6/7)*6 (G/G and G/A).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>The first day of treatment to the date that disease progression is reported; assessed up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>the first day of treatment to death or last survival confirm date; assesed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>the ratio between the number of responders and number of patients assessable for tumor response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>the first date of treatment to 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>the day before every cycle of chemotherapy; 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 90mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan 65mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of small-cell lung cancer

          -  Extensive-stage disease, defined as disease extending beyond one hemithorax involving
             contralateral mediastinal, hilar or supraclavicular lymph nodes, and/or pleural
             effusion.

          -  Males or females between 18 to 75 years

          -  No prior chemotherapy, if the surgery or radiotherapy has been administered, the
             interval is at least above four weeks.

          -  Performance status of 0-2 on the ECOG criteria. Expected survival is above three
             months.

          -  At least one unidimensional measurable lesion meeting Response Evaluation Criteria in
             Solid Tumors (RECIST. 2000).

          -  Patient compliance that allow adequate follow-up. Informed consent from patient or
             patient's relative.

          -  Adequate hematologic (neutrophil count &gt;= 1,500/uL, platelets &gt;= 100,000/uL), hepatic
             (transaminase =&lt; upper normal limit(UNL)x2.5, bilirubin level =&lt; UNL x 1.5), and renal
             (creatinine =&lt; UNL) function

          -  The gene type of UGT1A1 *28 is 6/6 and 6/7.

          -  If female: childbearing potential either terminated by surgery, radiation, or
             menopause, or attenuated by use of an approved contraceptive method (intrauterine
             device [IUD], birth control pills, or barrier device) during and for 3 months after
             trial. If male, use of an approved contraceptive method during the study and 3 months
             afterwards. Females with childbearing potential must have a urine negative HCG test
             within 7 days prior to the study enrollment.

          -  No concomitant prescriptions including cyclosporin A, valproic acid, phenobarbital,
             phenytoin, ketoconazole.

        Exclusion Criteria:

          -  Non small cell lung cancer and carcinoid

          -  Medically uncontrolled severe diarrhea in recent three weeks.

          -  Inability to comply with protocol or study procedures.

          -  Medically uncontrolled serious heart, lung, neurological, psychological, metabolic
             disease

          -  Second primary malignancy that is clinically detectable at the time of consideration
             for study enrollment.

          -  Pregnant or breast-feeding.

          -  Enrollment in other study within 30 days

          -  Brain metastasis with symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueqin Yang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daping Hospital, Third Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xueqin Yang, M.D.</last_name>
    <phone>+86-023-68757158</phone>
    <email>yangxueqin@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiying Li, M.D.</last_name>
      <phone>13637808684</phone>
    </contact>
    <investigator>
      <last_name>Qiying Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dairong Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinan Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Xiong, M.D.</last_name>
      <phone>+86-13512345225</phone>
    </contact>
    <investigator>
      <last_name>Wei Xiong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Zhu, M.D.</last_name>
      <phone>+86-15923366951</phone>
    </contact>
    <investigator>
      <last_name>Bo Zhu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43.</citation>
    <PMID>16648503</PMID>
  </reference>
  <reference>
    <citation>Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol. 2013;30(3):604. doi: 10.1007/s12032-013-0604-x. Epub 2013 May 18.</citation>
    <PMID>23686699</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Meng X, Wang Y, Yan W, Yang J. Comprehensive analysis of UGT1A1 genetic polymorphisms in Chinese Tibetan and Han populations. Biochem Genet. 2012 Dec;50(11-12):967-77. doi: 10.1007/s10528-012-9536-y. Epub 2012 Sep 16.</citation>
    <PMID>22983686</PMID>
  </reference>
  <reference>
    <citation>Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91.</citation>
    <PMID>11784874</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <last_update_submitted>March 31, 2016</last_update_submitted>
  <last_update_submitted_qc>March 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Xueqin Yang</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <keyword>Irinotecan; Cisplatin; Small-cell lung cancer; UGT1A1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

